Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2025-12-25 @ 12:10 AM
NCT ID:
NCT06200558
Eligibility Criteria:
Inclusion Criteria:
* Patients aged \>18y
* Cytological or Histologically confirmed diagnosis of PC
* Histologically or radiologically confirmed diagnosis of metastatic disease and
For ARON-3S
▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)
For ARON-3Lu
▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC
For ARON-3GEN
* HRD POSITIVE STATUS
* Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
Exclusion Criteria:
* Patients without histologically confirmed diagnosis of PC
* Patients without histologically or radiologically confirmed metastatic disease and
For ARON-3S
▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section
For ARON-3Lu
▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC
For ARON-3GEN
* HRD NEGATIVE STATUS
* Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06200558
Study Brief:
Protocol Section:
NCT06200558